Risk factors of side effects of antituberculosis drugs;Facteurs de risque des effets indesirables des antituberculeux

Tunisie Medicale

Volumn 84, Issue 8, 2006, Pages 487-491

  El Gharbi, Leila ^a   Baccar, Mohamed Ali ^a   Azzabi, Saloua ^a   Aouina, Hichem ^a   Kallel, Houda ^a   Daghfous, Riadh ^b   Bouacha, Hend ^a  

^a CHARLES NICOLLE HOSPITAL   (Tunisia)

^b UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

Antituberculosis; Risk factors; Side effects

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OTOTOXICITY; RISK ASSESSMENT; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 33845364636     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Dixie E, Snider JR, Gus JC. Isoniazid -associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992;145:494-97.
2. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious Side Effects from first-line antituberculosis drug among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003 ; 167: 1472-77.
3. Danan G. Définition et critères d'imputabilité des atteintes hépatiques médicamenteuses. Conclusion d'une réunion internationale de consensus gastro-entérogène. Clin Biol1993, 17 : 18-21
4. Ormerod LP. For a subcommittee of the joint tuberculosis committee. Chemotherapy and management of tuberculosis in the United Kingdoms : recommendations of the joint tuberculosis committee of the British society. Thorax 1990 ; 45 : 403-08
5. Van den Brande P, Van Steenbergen W, Vervoort G, Demedts M. Aging and hepatotoxicity of isoniazid and rifampicin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995 ; 152 : 1705-08.
6. Jassens JP and all. Clinical epidemiology and treatment of tuberculosis in elderly patients. Schweiz-Med-Wochenschr 1999;129:80-89.
7. Schaberg T, Rebhan K, Lode H. Risk factors of side effects of isoniazid rifampicin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Resp J 1996;9:2026-30.
8. Leophonte. Modalités thérapeutiques de la tuberculose pulmonaire. Rev Prat 1990 ; 40 : 719-24.
9. Girling DJ. Adverse effects of antituberculosis drugs. Drugs 1992 ; 23 : 56-74.
10. Canadian Medical Association Journal. August 24,1999. Selection: Edication/clinicals basis. Tuberculosis treatment (magazine).
11. Decroix G et all. Hepatic toxicity. Rev Fr Mal Respir 1997; 1:37-44.
12. Huchon GJ, Uzzan BE. Pharmacologie des antituberculeux. Médecine hygiène 1982 ; 40 : 1509-20.
13. Cohen LK. Isontazid induced acne and pellagra. Arcg Dermatol 1974;109:377-81.
14. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy : a 7-year survey from a public health tuberculosis clinic. JAMA 1999 ; 281 : 1014-18.
15. Gronhagen R. Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis : Am Rev Resp Dis 1978;118 :461-66.
16. Gonzalez Montaner LJ, Dambrosi A, Manassero M, Dambrosi V, Dambrosi ML. Adverse effects of antituberculosis drugs causing changes in treatment. Tubercle 1982 ; 63 : 291-94.